Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours

Journal of Clinical Pathology

Volumn 57, Issue 5, 2004, Pages 504-512

  Jubb, A M ^a   Pham, T Q ^a   Hanby, A M ^b   Frantz, G D ^a   Peale, F V ^a   Wu, T D ^a   Koeppen, H W ^a   Hillan, K J ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; UPREGULATION; URINARY TRACT CANCER;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL HYPOXIA; DNA, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2442625634     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.012963     Document Type: Article

References (68)

1. Folkmon J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Gimbrone MA Jr, Cotran RS, Leapman SB, et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974;52:413-27.
3. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164:491-502.
4. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
5. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
6. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8(suppl 4):S62-7.
7. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-14.
8. 2 sensing. Science 2001;292:464-8.
9. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
10. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
11. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1 alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A 2000;97:4748-53.
12. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149-62.
13. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15.
14. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
15. Jiang BH, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271:17771-8.
16. Gerber HP, Condorelli F, Park J, et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997;272:23659-67.
17. Levy AP, Levy NS, Wegner S, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40.
18. Liu Y, Cox SR, Marita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-43.
19. Madan A, Curtin PT. A 24-base-poir sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc Natl Acad Sci U S A 1993;90:3928-32.
20. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
21. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
22. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;270:12607-13.
23. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
24. Warren RS, Yuan H, Matli MR, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996;271:29483-8.
25. Soh EY, Sobhi SA, Wong MG, et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 1996;120:944-7.
26. Shifren JL, Mesiano S, Taylor RN, et al. Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. J Clin Endocrinol Metab 1998;83:1342-7.
27. Pupilli C, Lasagni L, Romognani P, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-55.
28. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
29. Manders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002;87:772-8.
30. De Paola F, Granato AM, Scarpi E, et al. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 2002;98:228-33.
31. Ellis LM, Takahashi Y, Liu W, et al. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5(suppl 1):11-15.
32. Kang SM, Maeda K, Onoda N, et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997;74:502-7.
33. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53.
34. Cascinu S, Stacciali MP, Gasporini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000;6:2803-7.
35. Cascinu S, Groziono F, Volentini M, et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylote synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001;12:239-44.
36. Shen GH, Ghozizadeh M, Kawanomi O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83:196-203.
37. Ogawa S, Kaku T, Kobayashi H, et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 2002;176:111-18.
38. O'Byrne KJ, Dobbs N, Propper D, et al. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999;353:1494-5.
39. Cheng WF, Chen CA, Lee CN, et al. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 2000;96(5 Pt 1):721-6.
40. Mineta H, Miura K, Ogino T, et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000;83:775-81.
41. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
42. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-21.
43. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19:3660-8.
44. Hui EP, Chon AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-604.
45. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9.
46. Giatromanolaki A, Koukourokis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992-8.
47. Ferrara N, Winer J, Burton T, et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 1993;91:160-70.
48. Jubb AM, Landon TH, Burwick J, et al. Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol 2003;200:577-88.
49. Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001;195:72-9.
50. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-51.
51. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
52. Frantz GD, Pham TQ, Peale FV Jr, et al. Detection of novel gene expression in poraffin-embedded tissues by isotopic in situ hybridization in tissue microarrays. J Pathol 2001;195:87-96.
53. Lu LH, Gillett NA. An optimized protocol for in situ hybridization using PCR-generated 33P-labeled probes. Cell Vision 1994;1:169-76.
54. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003;19:368-75.
55. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997;80:1945-53.
56. Obermair A, Kucero E, Mayerhafer K, et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 1997;74:455-8.
57. Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999;84:293-8.
58. Linderholm B, Lindh B, Tavelin B, et al. p53 and vascular-endothelial- growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000;89:51-62.
59. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-60.
60. Hanrahan V, Currie M, Gunningham S, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003;200:183-94.
61. Maeda K, Kang SM, Onoda N, et al. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 1999;86:566-71.
62. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76.
63. Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45:216-24.
64. Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999;85:1323-30.
65. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol 2002;197:677-83.
66. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
67. Ravindranath N, Wion D, Brachet P, et al. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432-43.
68. Jakson M, Bentel J, Tilley W. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2040-1.